It has been announced that VX-150 and VX-548 target the Nav1.8 ion channel, showing potential for pain relief.
The paper using QPatch Compact focuses on the study of the inhibition of the Nav1.8 ion channel by two new analgesic compounds, VX-150 and VX-548. The Nav1.8 channel is a major target in sensory neurons that detect pain and is extremely important for pain-related therapies. This research, conducted by a professor's laboratory at Harvard Medical School, utilized the QPatch Compact semi-automated patch clamp system to perform voltage clamp recordings and analyze the effects of these compounds on Nav1.8 sodium currents. *For more details, you can view the related links. Please feel free to contact us for more information.*
Inquire About This Product
basic information
*You can view the detailed content of the article through the related link. For more information, please feel free to contact us.*
Price range
Delivery Time
Applications/Examples of results
*You can view the detailed content of the article through the related link. For more information, please feel free to contact us.*
catalog（3）
Download All Catalogs
News about this product（1）
Company information
Sophion Bioscience was founded by a passionate group of electrophysiologists with a common goal of providing objective patch clamp results quickly and accurately, independent of the experimenter's skill. We have grown from a small startup in Denmark to a global company, but our passion and commitment to providing high-performance patch clamp solutions remain unchanged. Through exceptional technical service and application support, we back our customers in achieving their goals. Additionally, with the continuous development of the QPatch and Qube platforms, we ensure uncompromising data quality in a user-friendly environment, from assay setup to data analysis.